Johnson & Johnson's COVID-19 vaccine is 73.6% effective, according to new real-world study

eligibility for the Covid 19 booster shot has been expanded Now. Many americans are allowed to get the third does, even if they don't know it yet. The Centers for Disease Control and Prevention's new guidelines state anyone who received either vaccine six months ago and are 65 years or older can get the booster shot. Those who are 18 years or older living in long term care settings have underlying medical conditions and work or live in high risk settings are also able to get the third shot reports. The hill, both fighter and Moderna have been found to be 95% effective against symptomatic Covid 19 johnson and johnson is set to be 66% effective against it. Anyone who received the J and J vaccine at least two months ago is also eligible to receive the booster shot. Vaccinations are allowed to be mixed according to the Food and Drug Administration and according to data, over 108 million americans are due to receive the booster shot as they've been vaccinated for over six months.

Video above: More people qualify for the vaccine booster shotData from a real-world study assessing Johnson & Johnson's COVID-19 vaccine finds it is 73.6% effective, according to research published Tuesday in the journal JAMA Network Open.The study evaluated patients within the Mayo Clinic Health System between February and July of this year. The researchers followed nearly 9,000 patients vaccinated with the J&J vaccine and nearly 89,000 patients who were unvaccinated. They looked specifically to see how many of them tested positive for COVID-19.Among the 8,889 vaccinated patients, 60 had a positive PCR test. Among the 88,898 unvaccinated patients, 2,236 had a positive PCR test. The researchers concluded the vaccine was 73.6% effective and led to a 3.73-fold reduction in coronavirus infections. The finding is similar to clinical trial data that found the vaccine was 66.9% effective against moderate to severe COVID-19.The new research showed a reduction in severe cases, especially hospitalizations, but too few people got COVID-19 among the vaccinated group to draw a strong conclusion as to how well the vaccine prevented deaths.In an accompanying commentary, Dr. Mohammad Sajadi of the Institute of Human Virology at the University of Maryland School of Medicine argued that the findings are part of a growing body of work that suggests "room for improvement" with the J&J vaccine."What is becoming more clear with time is that the single-dose regimen of the vaccine seems to be inferior to the mRNA vaccines in terms of ," Sajadi wrote, comparing the J&J vaccine to a different type of COVID-19 vaccine that is made by Pfizer/BioNTech and Moderna.Sajadi noted that the same group of researchers who conducted this latest J&J study had previously looked at vaccine effectiveness of the Pfizer and Moderna COVID-19 vaccines, which had "significantly higher" efficacy. In that study, the real-world effectiveness of the Pfizer vaccine was 86.1%. For Moderna, it was 93.3%.In September, a head-to-head study of all three vaccines found the Moderna vaccine is slightly more effective than Pfizer's in real-life use in keeping people out of the hospital.Moderna's vaccine provided 93% protection against hospitalization, and Pfizer's was 88% effective.Sajadi said improvement of the J&J vaccine may come in a second dose or a booster of an mRNA COVID-19 vaccine.

Video above: More people qualify for the vaccine booster shot

Data from a real-world study assessing Johnson & Johnson's vaccine finds it is 73.6% effective, according to research published Tuesday in the journal JAMA Network Open.

The study evaluated patients within the Mayo Clinic Health System between February and July of this year. The researchers followed nearly 9,000 patients vaccinated with the J&J vaccine and nearly 89,000 patients who were unvaccinated. They looked specifically to see how many of them tested positive for COVID-19.

Among the 8,889 vaccinated patients, 60 had a positive PCR test. Among the 88,898 unvaccinated patients, 2,236 had a positive PCR test. The researchers concluded the vaccine was 73.6% effective and led to a 3.73-fold reduction in coronavirus infections. The finding is similar to clinical trial data that found the vaccine was 66.9% effective against moderate to severe COVID-19.

The new research showed a reduction in severe cases, especially hospitalizations, but too few people got COVID-19 among the vaccinated group to draw a strong conclusion as to how well the vaccine prevented deaths.

In an accompanying commentary, Dr. Mohammad Sajadi of the Institute of Human Virology at the University of Maryland School of Medicine argued that the findings are part of a growing body of work that suggests "room for improvement" with the J&J vaccine.

"What is becoming more clear with time is that the single-dose regimen of the [Johnson & Johnson COVID-19] vaccine seems to be inferior to the mRNA vaccines in terms of [vaccine effectiveness]," Sajadi wrote, comparing the J&J vaccine to a different type of COVID-19 vaccine that is made by Pfizer/BioNTech and Moderna.

Sajadi noted that the same group of researchers who conducted this latest J&J study had previously looked at vaccine effectiveness of the Pfizer and Moderna COVID-19 vaccines, which had "significantly higher" efficacy. In that study, the real-world effectiveness of the Pfizer vaccine was 86.1%. For Moderna, it was 93.3%.

In September, of all three vaccines found the Moderna vaccine is slightly more effective than Pfizer's in real-life use in keeping people out of the hospital.

Moderna's vaccine provided 93% protection against hospitalization, and Pfizer's was 88% effective.

Sajadi said improvement of the J&J vaccine may come in a second dose or a booster of an mRNA COVID-19 vaccine.

��vlog